Los Angeles Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

Los Angeles Capital Management’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$272K	Buy	+25,311	New	+$207K	﹤0.01%	1082

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCA

Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Los Angeles Capital Management's FENC Position: Q2 2026 in Review

Los Angeles Capital Management opened a new position in Fennec Pharmaceuticals (FENC) in Q2 2026: 25,311 shares worth $272K. The stake represents ﹤0.01% of the portfolio and ranks #1082 among its holdings.

104 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

Los Angeles Capital Management held 25,311 shares of Fennec Pharmaceuticals worth $272K as of Q2 2026.
Fennec Pharmaceuticals was a new Los Angeles Capital Management position in Q2 2026.
Fennec Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1082 holding.
104 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.